S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.10
+360.20
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.49
+1.81
+10.85%
PCVX · Vaxcyte, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$63.25
-3.00
(-4.53%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$63.25
$63.12
$67.17
52-WEEK RANGE
$63.25
$39.87
$90.75
What's happening
- PCVX is down 4.53% today, trading at $63.25. — Live quote
- Volume today (259,410) is well below its 3-month average of 1,853,330. (Finnhub fundamentals)
- Reports earnings on 2026-11-09, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-1.97 actual vs. $-2.10 estimated (+6.0%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
PCVX
+43.54%
vs S&P 500
+30.76%
1-YEAR RETURN
PCVX
+54.38%
vs S&P 500
+39.82%
6-MONTH RETURN
PCVX
+6.48%
3-MONTH RETURN
PCVX
+14.11%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.97
Est. $-2.10
BEAT +6.0%
2026-04-26 (Q1 2026)
$-2.30
Est. $-1.79
MISS -28.7%
2026-01-26 (Q4 2025)
$-1.80
Est. $-1.55
MISS -16.4%
2025-10-26 (Q3 2025)
$-1.56
Est. $-1.29
MISS -20.5%
Valuation Measures & Ratios
Enterprise Value4$9.80B
Forward P/E5—
PEG Ratio6-0.10
Price / Sales (TTM1)—
Price / Book73.04
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-37.57%
Return on Assets (ROA9)-33.62%
Avg Volume (3M)1,853,330
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $8.38B | $8.09B | $4.91B | $4.44B | $5.11B |
| P/E | -8.52 | -9.63 | -7.88 | -8.24 | -10.94 |
| Price/Book | 3.04 | 2.70 | 1.70 | 1.45 | 1.60 |
| EV/EBITDA | -7.42 | -7.97 | -5.95 | — | — |
| ROE | -35.69% | -28.06% | -21.54% | -17.55% | -14.61% |
| ROA | -31.37% | -25.11% | -19.65% | -16.31% | -13.84% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short17,290,712
Change from Prior Settlement+7.18%
% of Float—
Days to Cover (Short Ratio)11.39
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +54.4%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-10-09; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on PCVX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$302.8M | -$345.9M | -$242.4M | -$226.2M | -$180.8M | -$139.9M | -$153.0M | -$114.5M |
| Net income | -$284.3M | -$320.6M | -$212.8M | -$166.6M | -$140.7M | -$103.1M | -$128.7M | -$95.0M |
| EPS (diluted) | $-1.97 | $-2.30 | $-1.56 | $-1.22 | $-1.04 | $-0.83 | $-1.10 | $-0.85 |
| EPS (basic) | $-1.97 | $-2.30 | $-1.56 | $-1.22 | $-1.04 | $-0.83 | $-1.10 | $-0.85 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $3.14B | $3.35B | $3.00B | $3.17B | $3.31B | $3.38B | $3.51B | $3.56B |
| Total liabilities | $380.2M | $352.3M | $317.2M | $278.7M | $234.0M | $178.1M | $205.5M | $142.1M |
| Stockholders' equity | $2.76B | $3.00B | $2.69B | $2.89B | $3.07B | $3.20B | $3.31B | $3.42B |
| Total current assets | $1.55B | $1.81B | $1.63B | $1.77B | $1.72B | $1.72B | $1.79B | $2.21B |
| Total current liabilities | $271.3M | $242.1M | $205.8M | $200.0M | $154.5M | $97.0M | $140.2M | $123.8M |
| Cash & equivalents | $183.2M | $260.8M | $174.0M | $281.1M | $306.7M | $346.9M | $387.9M | $1.05B |
| Marketable securities (current) | $1.30B | $1.48B | $1.39B | $1.43B | $1.35B | $1.32B | $1.36B | $1.13B |
| Other current assets | — | — | $1.6M | — | — | — | $2.0M | $3.4M |
| Marketable securities (non-current) | $1.02B | $1.00B | $881.7M | $959.3M | $1.17B | $1.28B | $1.39B | $1.09B |
| Property, plant & equipment | $260.4M | $260.7M | $257.4M | $253.5M | $242.3M | $217.2M | $198.0M | $163.2M |
| Other non-current assets | $192.6M | $155.5M | $118.8M | $106.7M | $95.3M | $76.3M | $64.4M | $60.0M |
| Accounts payable | $100.9M | $63.1M | $70.9M | $49.0M | $31.4M | $20.5M | $48.5M | $18.2M |
| Accrued liabilities | $24.7M | $30.2M | $31.1M | $24.6M | $32.2M | $26.0M | $29.1M | $30.8M |
| Other non-current liabilities | — | — | $100.0K | — | — | — | $100.0K | — |
| Common stock & paid-in capital | $148.0K | $147.0K | $134.0K | $133.0K | $133.0K | $132.0K | $128.0K | $127.0K |
| Retained earnings | -$2.76B | -$2.48B | -$2.15B | -$1.91B | -$1.70B | -$1.53B | -$1.39B | -$1.25B |
| Accumulated other comprehensive income (loss) | -$7.5M | -$6.8M | $1.6M | $856.0K | -$1.9M | -$322.0K | -$3.9M | $139.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$232.5M | -$280.6M | -$224.8M | -$143.3M | -$121.2M | -$166.3M | -$111.4M | -$60.7M |
| Investing cash flow | $147.7M | -$233.4M | $115.1M | $121.2M | $77.7M | $123.3M | -$557.2M | -$917.0M |
| Financing cash flow | $5.7M | $601.6M | $2.4M | -$3.7M | $2.5M | $759.0K | $4.9M | $1.52B |
| Free cash flow | -$236.8M | -$282.7M | -$227.5M | -$147.1M | -$123.0M | -$171.7M | -$115.4M | -$65.7M |
| Capital expenditures | $4.3M | $2.1M | $2.7M | $3.8M | $1.8M | $5.4M | $4.0M | $4.9M |
| Depreciation & amortization | $3.0M | $2.9M | $7.5M | $3.1M | $2.9M | $3.0M | $2.9M | $1.8M |
| Share-based compensation | $41.2M | $38.0M | $36.0M | $35.3M | $36.9M | $30.6M | $24.4M | $21.3M |
| Change in accounts payable | $31.6M | -$269.0K | $21.7M | $17.9M | $9.5M | -$29.2M | $31.3M | $8.3M |
| Purchases of investments | $268.7M | $584.1M | $292.6M | $255.3M | $349.1M | $314.5M | $815.2M | $1.23B |
| Sales/maturities of investments | $22.5M | $24.9M | $68.2M | $38.3M | $42.1M | $26.1M | $24.5M | $26.5M |
| Tax withholding on stock comp | $2.1M | $9.3M | $1.0M | $4.0M | $717.0K | $5.3M | $1.1M | $9.3M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
| EPS (basic) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $3.00B | $3.51B | $1.41B | $1.01B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Stockholders' equity | $2.69B | $3.31B | $1.24B | $953.6M | $284.0M |
| Total current assets | $1.63B | $1.79B | $1.10B | $942.6M | $256.3M |
| Total current liabilities | $205.8M | $140.2M | $145.3M | $40.5M | $28.7M |
| Cash & equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M |
| Marketable securities (current) | $1.39B | $1.36B | $682.8M | $96.7M | $177.0M |
| Other current assets | $1.6M | $2.0M | $2.1M | $2.0M | — |
| Marketable securities (non-current) | $881.7M | $1.39B | $162.7M | $26.5M | $27.1M |
| Property, plant & equipment | $257.4M | $198.0M | $79.6M | $10.4M | $8.0M |
| Other non-current assets | $118.8M | $64.4M | $37.6M | $4.6M | $4.1M |
| Accounts payable | $70.9M | $48.5M | $14.6M | $9.8M | $6.8M |
| Accrued liabilities | $31.1M | $29.1M | $59.8M | $15.4M | $8.8M |
| Other non-current liabilities | $100.0K | $100.0K | $0 | $9.0K | $96.0K |
| Common stock & paid-in capital | $134.0K | $128.0K | $98.0K | $82.0K | $56.0K |
| Retained earnings | -$2.15B | -$1.39B | -$924.4M | -$522.1M | -$298.6M |
| Accumulated other comprehensive income (loss) | $1.6M | -$3.9M | $179.0K | -$361.0K | -$241.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Investing cash flow | $437.4M | -$2.01B | -$773.3M | $74.6M | -$212.3M |
| Financing cash flow | $2.0M | $2.45B | $639.8M | $861.5M | $17.8M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Capital expenditures | $13.7M | $22.4M | $16.1M | $5.8M | $6.6M |
| Depreciation & amortization | $16.4M | $7.0M | $3.2M | $2.8M | $1.8M |
| Share-based compensation | $138.8M | $84.8M | $48.8M | $23.6M | $10.7M |
| Change in accounts payable | $19.9M | $34.6M | $11.2M | $2.9M | -$12.5M |
| Purchases of investments | $1.21B | $3.09B | $1.33B | $102.7M | $336.3M |
| Sales/maturities of investments | $174.7M | $67.0M | $12.6M | $14.5M | $30.1M |
| Tax withholding on stock comp | $11.0M | $14.3M | $3.9M | $861.0K | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding PCVX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers97.6%
Shares Outstanding144,494,106
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| FMR LLC | 20,852,907 | $1.21B | 14.43% | +26.4% | 2026-08-13 |
| Jupiter Topco LLC | 17,965,847 | $1.04B | 12.43% | +0.0% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 12,207,450 | $709.6K | 8.45% | +0.7% | 2026-08-14 |
| BlackRock, Inc. | 12,068,129 | $701.5M | 8.35% | +10.0% | 2026-08-07 |
| RA CAPITAL MANAGEMENT, L.P. | 11,474,599 | $667.0M | 7.94% | +0.0% | 2026-08-14 |
| WELLINGTON MANAGEMENT GROUP LLP | 7,001,565 | $407.0M | 4.85% | +24.7% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,593,551 | $383.3M | 4.56% | +5.0% | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6,348,679 | $369.0M | 4.39% | +1.3% | 2026-06-30 |
| State Street Corp | 5,351,698 | $311.1M | 3.70% | +20.5% | 2026-08-07 |
| Deep Track Capital, LP | 4,300,000 | $250.0M | 2.98% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 3,459,363 | $201.1M | 2.39% | +8.1% | 2026-08-12 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2,988,999 | $173.8K | 2.07% | +206.1% | 2026-08-14 |
| Kynam Capital Management, LP | 2,922,335 | $169.9M | 2.02% | +0.0% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2,472,428 | $143.7M | 1.71% | -32.2% | 2026-08-12 |
| Caligan Partners LP | 2,188,636 | $127.2M | 1.51% | +6.2% | 2026-08-14 |
| Paradigm Biocapital Advisors LP | 2,127,852 | $123.7M | 1.47% | -55.6% | 2026-08-14 |
| Bellevue Group AG | 1,971,935 | $114.6M | 1.36% | +65.6% | 2026-08-13 |
| D. E. Shaw & Co., Inc. | 1,901,872 | $110.6M | 1.32% | -33.6% | 2026-08-14 |
| MAVERICK CAPITAL LTD | 1,613,242 | $93.8M | 1.12% | +17.1% | 2026-08-14 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,464,812 | $85.1M | 1.01% | +4.3% | 2026-08-14 |
| Sixth Street Partners Management Company, L.P. | 1,464,812 | $85.1M | 1.01% | +0.0% | 2026-08-13 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,425,470 | $82.9M | 0.99% | +3.9% | 2026-08-13 |
| EVENTIDE ASSET MANAGEMENT, LLC | 1,380,219 | $80.2M | 0.96% | +0.4% | 2026-08-14 |
| Goldman Sachs Group Inc | 1,350,760 | $78.5M | 0.93% | +5.9% | 2026-08-14 |
| Northern Trust Corp | 1,280,172 | $74.4M | 0.89% | +11.9% | 2026-08-12 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-18 to 2026-10-05
Recent transactions
- Insiders have net sold 163,838 shares over the last 182 days, across 0 purchases and 40 sales.
- Most recent: Wassil Jim (EVP, Chief Scientific Ofc, COO) — Option exercise of 18,000 shares on 2026-10-05.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)163,838 sh(40 txns)
Net Shares-163,838
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Wassil Jim | EVP, Chief Scientific Ofc, COO | Option exercise | 2026-10-05 | 18,000 |
| Cowan Elvia | SVP, Finance & CAO | Option exercise | 2026-10-05 | 19,000 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 2026-09-08 | 17,056 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 2026-09-08 | 7,155 |
| Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 2026-09-08 | 7,651 |
| Jodar Luis | Chief Medical Officer | Grant / award | 2026-09-04 | 52,632 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-05 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Option exercise | 18,000 | $5.35 |
| 2026-10-05 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Open market sale | 18,000 | $86.74 |
| 2026-10-05 | Cowan Elvia | SVP, Finance & CAO | Option exercise | 19,000 | $25.92 |
| 2026-10-05 | Cowan Elvia | SVP, Finance & CAO | Open market sale | 19,000 | $86.74 |
| 2026-10-01 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Option exercise | 2,250 | $5.35 |
| 2026-10-01 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Open market sale | 2,155 | $56.65 |
| 2026-10-01 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Open market sale | 95 | $57.09 |
| 2026-09-09 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Open market sale | 1,334 | $59.52 |
| 2026-09-08 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 17,056 | $60.36 |
| 2026-09-08 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 7,155 | $60.36 |
| 2026-09-08 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 7,651 | $60.36 |
| 2026-09-08 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 1,327 | $60.36 |
| 2026-09-08 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Tax withholding | 5,459 | $60.36 |
| 2026-09-04 | Wassil Jim | EVP, Chief Scientific Ofc, COO | Open market sale | 1,381 | $61.16 |
| 2026-09-04 | Jodar Luis | Chief Medical Officer | Grant / award | 52,632 | $0.00 |
| 2026-09-02 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 1,432 | $61.58 |
| 2026-09-02 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 3,427 | $61.58 |
| 2026-09-02 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1,432 | $61.58 |
| 2026-09-02 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 659 | $61.58 |
| 2026-09-02 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 326 | $61.58 |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Option exercise | 2,250 | $5.35 |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 1,537 | $60.89 |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 713 | $61.48 |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 924 | $60.95 |
| 2026-09-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 303 | $61.42 |
| 2026-08-31 | Wassil Jim | CHIEF OPERATING OFFICER | Tax withholding | 1,273 | $60.74 |
| 2026-08-31 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Tax withholding | 2,862 | $60.74 |
| 2026-08-31 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Tax withholding | 1,273 | $60.74 |
| 2026-08-31 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Tax withholding | 361 | $60.74 |
| 2026-08-31 | Cowan Elvia | SVP, Finance & CAO | Tax withholding | 243 | $60.74 |
| 2026-08-05 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Option exercise | 17,000 | $24.79 |
| 2026-08-05 | Dhaliwal Harpreet S. | Chief Technical Ops Officer | Open market sale | 17,000 | $55.00 |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Option exercise | 2,250 | $5.35 |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 861 | $53.50 |
| 2026-08-03 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 1,389 | $54.09 |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Option exercise | 10,000 | $5.35 |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Open market sale | 6,956 | $53.76 |
| 2026-08-03 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Open market sale | 3,044 | $54.18 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Option exercise | 16,198 | $2.03 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 11,783 | $55.52 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 4,415 | $55.93 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 756 | $55.52 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 244 | $55.96 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 622 | $55.54 |
| 2026-07-27 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 378 | $55.91 |
| 2026-07-06 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Option exercise | 10,000 | $5.35 |
| 2026-07-06 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Open market sale | 7,913 | $57.16 |
| 2026-07-06 | GUGGENHIME ANDREW | PRESIDENT AND CFO | Open market sale | 2,087 | $57.76 |
| 2026-07-01 | Wassil Jim | CHIEF OPERATING OFFICER | Option exercise | 516 | $5.35 |
| 2026-07-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 1,788 | $56.03 |
| 2026-07-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 456 | $57.47 |
| 2026-07-01 | Wassil Jim | CHIEF OPERATING OFFICER | Open market sale | 6 | $57.82 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 6,683 | $54.27 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 9,137 | $55.27 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 6,417 | $56.12 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 312 | $54.34 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 356 | $55.23 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 332 | $55.99 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 207 | $54.22 |
| 2026-06-26 | PICKERING GRANT | CHIEF EXECUTIVE OFFICER | Open market sale | 602 | $55.30 |
Showing the most recent 60 transactions.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:22 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-09 | 8-K | 2026-10-06 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-07 | 4 | 2026-10-05 | View on SEC.gov → |
| 2026-10-05 | 8-K | 2026-10-05 | View on SEC.gov → |
| 2026-10-02 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-04 | View on SEC.gov → |
| 2026-09-03 | 8-K | 2026-08-31 | View on SEC.gov → |
Recent news
Headlines about PCVX (Vaxcyte, Inc.). Links open the publisher — we don’t host full articles.
-
Vaxcyte slips as investors digest recent financing after Phase 3 vaccine data
Quiver Quantitative · 2026-10-21 -
Cantor Fitzgerald sets USD 120 target for Vaxcyte stock
AD HOC NEWS · 2026-10-20 -
PCVX Nov 2026 90.000 put (PCVX261120P00090000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-19 -
Cantor Fitzgerald reiterates Vaxcyte stock rating on OPUS-1 data
Investing.com · 2026-10-19 -
Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX)
Seeking Alpha · 2026-10-19 -
Vaxcyte: Vaccine Titan In The Making
SeekingAlpha · 2026-10-19 -
Vaxcyte Stock Sinks as Massive Cash Raise Spooks Wall Street
TipRanks · 2026-10-18 -
Cantor Fitzgerald sets USD 120.00 target for Vaxcyte stock - ad-hoc-news.de
ad-hoc-news.de · 2026-10-17
No headlines in this category right now — try “All”.